MedTrace Logo

Mosunetuzumab for CLL MRD Clearance

NCT07052695 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-12-15

No results posted yet for this study

Summary

The goal of this study is to test mosunetuzumab given alone or in combination with a Bruton tyrosine kinase inhibitor (BTKi, such as ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib) in participants with CLL (chronic lymphocytic leukemia) or small lymphocytic lymphoma (SLL).

The names of the study drugs in this research study are:

* Mosunetuzumab
* BTK inhibitor: Ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib

Conditions

Interventions

DRUG

Mosunetuzumab

Subcutaneous injection of a CD20xCD3 bispecific antibody

DRUG

Ibrutinib

For participants who have been ibrutinib PO prior to enrollment

DRUG

Acalabrutinib

For participants who have been acalabrutinib PO prior to enrollment

DRUG

Zanubrutinib

For participants who have been zanubrutinib PO prior to enrollment

DRUG

Pirtobrutinib

For participants who have been pirtobrutinib PO prior to enrollment

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Inhye Ahn

    lead OTHER

Principal Investigators

  • Inhye Ahn, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-24
Primary Completion
2028-12-31
Completion
2032-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07052695 on ClinicalTrials.gov